Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.1600 (0.4%) ($11.1600 - $11.1600) on Tue. May. 30, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.19% (three month average) | RSI | 35 | Latest Price | $11.1600(0.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(61%) IBB(58%) IWO(44%) IWM(43%) IWN(41%) | Factors Impacting FOLD price | FOLD will decline at least -1.095% in a week (0% probabilities). TBT(-29%) VXX(-12%) UUP(-12%) VIXM(-2%) BNDX(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.095% (StdDev 2.19%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $11.57 | 5 Day Moving Average | $11.37(-1.85%) | 10 Day Moving Average | $11.39(-2.02%) | 20 Day Moving Average | $11.57(-3.54%) | To recent high | -12.9% | To recent low | 3.9% | Market Cap | $2.882b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |